Loading…

Medical Research Finder

Gut microbiota / Evidence-based microbiome knowledge (incl. AI chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

CP101 & Clostridioides difficile infection (CDI) (recurrent)

Welcome to meRfi-GM!

Please register to continue your trial period!

meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

CP101, as evidenced by NCT03110133, was more effective than a placebo in reducing Clostridioides difficile infection (CDI) (recurrent), and it maintained a safety profile comparable to the placebo.
Allegretti et al. 2025 Gastroenterology 168(2): 357-366

see also:
Fecal Microbiota Transplantation (FMT) & Clostridioides difficile infection (CDI) (recurrent)
[Probiotics (living agents) & Clostridioides difficile infection (recurrent) ](brain://NL81DwaEe06svkw0BsdQlg/ProbioticsLivingAgentsClostridioidesD…

First microbiome-based drug clears phase III, in clinical trial turnaround
Garber 2020 Nat. Rev. Drug Discov. 19: 655–656
Safety and Tolerability of CP101, a Full-Spectrum, Oral Microbiome Therapeutic for the Prevention of Recurrent Clostridioides difficile Infection: A Phase 2 Randomized Controlled Trial
Allegretti et al. 2025 Gastroenterology 168(2): 357-366

5/29/2026